Impact of combined pharmacologic treatment with clopidogrel and a statin on outcomes of patients with non-ST-segment elevation acute coronary syndromes: Perspectives from a large multinational registry

European Heart Journal

Volumn 26, Issue 11, 2005, Pages 1063-1069

  Lim, Michael J ^a   Spencer, Frederick A ^b   Gore, Joel M ^b   Dabbous, Omar H ^b   Agnelli, Giancarlo ^c   Kline Rogers, Eva M ^d   DiBenedetto, Donna ^b   Eagle, Kim A ^d   Mehta, Rajendra H ^e,f  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF PERUGIA   (Italy)

^d UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^e DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^f NONE   (United States)

Author keywords

Acute coronary syndrome; Clopidogrel; Non ST segment elevation; Statin

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; STATIN;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DEATH; DRUG POTENTIATION; FEMALE; HEART CATHETERIZATION; HEART DISEASE; HEART INFARCTION; HOSPITALIZATION; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PRIORITY JOURNAL; REVASCULARIZATION; STATISTICAL ANALYSIS; STROKE; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

ADOLESCENT; ADULT; AGED; ANGINA, UNSTABLE; ASPIRIN; CEREBROVASCULAR ACCIDENT; DRUG THERAPY, COMBINATION; FEMALE; HOSPITALIZATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 20544450827     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1093/eurheartj/ehi139     Document Type: Article

References (22)

1. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, Jones RH, Kereiakes D, Kupersmith J, Levin TN, Repine CJ, Schaeffer JW, Smith EE III, Steward DE, Theroux P. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 2002;40:1366-1374.
2. Bertrand ME, Simoons ML, Fox KA, Wallentin LC, Hamm CW, McFadden E, de Feyter PJ, Specchia G, Ruzyllo G. Management of acute coronary syndromes: acute coronary syndromes without persistent ST segment elevation; recommendations of the Task Force of the European Society of Cardiology. Eur Heart J 2000;21:1406-1432.
3. The TIMI IIIB Investigators. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction: results of the TIMI IIIB Trial. Circulation 1994;89:1545-1556.
4. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during Instability in Coronary artery disease Investigators. Lancet 1999;354:708-715.
5. Wallentin L, Lagerqvist B, Husted S, Kontny F, Stahle E, Swahn E. Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. FRISC II Investigators. Fast Revascularisation during Instability in Coronary artery disease. Lancet 2000;356:9-16.
6. Cannon CP, Weintraub WS, Demopoulos LA, Vicari R, Frey MJ, Lakkis N, Neumann FJ, Robertson DH, DeLucca PT, DiBattiste PM, Gibson CM, Braunwald E. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001;344: 1879-1887.
7. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (45). Lancet 1994;344:1383-1389.
8. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in lschaemic Disease (LIPID) Study Group. N Engl J Med 1998;339: 1349-1357.
9. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JMO, Wun CC, Davis BR, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335: 1001-1009.
10. Di Minno G, Tufano A, Cerbone AM. Antithrombotic drugs for older subjects. Guidelines formulated jointly by the Italian Societies of Haemostasis and Thrombosis (SISET) and of Gerontology and Geriatrics (SIGG). Nutr Metab Cardiovasc Dis 2001;11:41-62.
11. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001;285: 1711-1718.
12. Arntz HR, Agrawal R, Wunderlich W, Schnitzer L, Stem R, Fischer F, Schultheiss HP. Beneficial effects of pravastatin (+/- colestyramine/niacin) initiated immediately after a coronary event (the randomized Lipid-Coronary Artery Disease [L-CAD] Study). Am J Cardiol 2000;86:1293-1298.
13. Stenestrand U, Wallentin L. Early statin treatment following acute myocardial infarction and 1-year survival. JAMA 2001;285:430-436.
14. The Clopidogrel in Unstable angina to prevent Recurrent Events Trials Investigators (CURE). Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.
15. Steinhubl SR, Berger S, Mann JT, Fry ETA, DeLago A, Wilmer C, Topol EJ. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention. JAMA 2002;288:2411-2420.
16. Lau WC, Waskell LA, Watkins PB, Neer CJ, Horowitz K, Hopp AS, Tait AR, Carville DGM, Guyer KE, Bates ER. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation 2003;107:32-37.
17. The GRACE Investigators. Rationale and design of the GRACE (Global Registry of Acute Coronary Events) Project: a multinational registry of patients hospitalized with acute coronary syndromes. Am Heart J 2001;141:190-199.
18. Granger CB, Goldberg RJ, Dabbous O, Pieper KS, Eagle KA, Cannon CP, Van de Werf F, Avezum A, Goodman SG, Flather MD, Fox KAA. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med 2003;163:2345-2353.
19. Eagle KA, Goodman SG, Avezum A, Budaj A, Sullivan CM, Lopez-Sendon J. Practice variation and missed opportunities for reperfusion in ST-segment-elevation myocardial infarction: findings from the Global Registry of Acute Coronary Events (GRACE). Lancet 2002;359:373-377.
20. Eagle KA, Lim MJ, Dabbous OH, Pieper KS, Goldberg RJ, Van de Werf F, Goodman SG, Granger CB, Steg PG, Gore JM, Budaj A, Avezum A, Flather MD, Fox KAA. A validated prediction model for all forms of acute coronary syndrome: Estimating the risk of 6-month post-discharge death in an International Registry. JAMA 2004;291: 2727-2733.
21. Beckman JA, Creager MA, Libby P. Diabetes and Atherosclerosis: Epidemiology, Pathophysiology, and Management. JAMA 2002; 287:2570-2581.
22. Matetzky S, Shenkman B, Guetta V, Shechter M, Bienart R, Goldenberg I, Novikov I, Pres H, Savion N, Varan D, Hod H. Clopidogrel resistance is associated with increased risk of recurrent antithrombotic events in patients with acute myocardial infarction. Circulation 2004;109:3171-3175.